Meeting NewsVideo

VIDEO: Cal Roberts discusses move from Bausch to Lighthouse Guild

February 15, 2020
ORLANDO — At Cataract Surgery: Telling It Like It Is, Calvin Roberts, MD, discusses his decision to step down from his role as senior vice…

Meeting NewsVideo

VIDEO: Berdahl gives tips to entrepreneurship success

February 12, 2020
SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, John P. Berdahl, MD, discusses how to bring a product from an idea to market success.

Roberts leaving Bausch to lead Lighthouse Guild

February 10, 2020
Calvin Roberts, MD, is stepping down as senior vice president and chief medical officer of eye care at Bausch Health Companies to take over as…

Verana Health acquires PYA Analytics

February 5, 2020
Verana Health has acquired the technology assets and team from PYA Analytics, a large-scale data architecture solutions company, according to a press…

Ocumension to develop, commercialize Dexycu in greater China region

January 28, 2020
EyePoint Pharmaceuticals and Ocumension Therapeutics have signed an exclusive license agreement for the development and commercialization of Dexycu…

Ocuphire licenses oral drug candidate for retinal diseases

January 27, 2020
Ocuphire Pharma entered into an agreement with Apexian Pharmaceuticals for a worldwide sublicense for Apexian’s Ref-1 inhibitor program…

Bausch + Lomb expands parameters for toric contact lenses

January 22, 2020
Bausch + Lomb announced the launch of its expanded toric parameters for Biotrue OneDay for Astigmatism contact lenses. This expansion will provide…

Meeting News

Oyster Point’s dry eye nasal spray meets phase 2 endpoints

January 15, 2020
Oyster Point Pharma’s nasal spray treatment for dry eye disease has met its primary endpoints in the phase 2 MYSTIC trial, CEO and President…

CustomFlex artificial iris receives transitional pass-through payment status

January 15, 2020
The CustomFlex artificial iris was granted transitional pass-through payment status from CMS, effective Jan. 1, 2020. The artificial iris from VEO…

LumiThera completes Series C funding tranche

January 15, 2020
LumiThera has completed the second tranche of its Series C funding round to support clinical testing and commercialization of the Valeda light…

Meeting News

Santen plans entry in US glaucoma market

January 14, 2020
Santen plans to break into the U.S. glaucoma market in 2020 with the introduction of the DE-128 microshunt, according to a speaker at the 38th annual…

2020 AAO president begins term

January 13, 2020
Anne L. Coleman, MD, PhD, the American Academy of Ophthalmology’s 2020 president, has begun her term, according to a press release. Coleman…

ICYMI: Last week’s leading headlines

January 12, 2020
Keep up to date with the big news in ophthalmology. Here are some important stories you might have missed on Healio.com/OSN from the past week:

Tarsus raises $60 million in Series B financing

January 10, 2020
Tarsus Pharmaceuticals announced the completion of $60 million in Series B financing that will be used to initiate a phase 2b/3 trial of topical…

Eyevensys closes on $30 million Series B financing

January 10, 2020
Eyevensys, a Paris-based biotechnology company, has closed a round of $30 million in Series B financing intended for development of EYS606 for the…

Alimera refinances debt with Solar Capital

January 6, 2020
Alimera Sciences has entered into a new $45 million term loan agreement with Solar Capital Partners, refinancing its debt facility, according to a…

EyeGate completes $5 million registered direct offering

January 6, 2020
EyeGate Pharmaceuticals has completed a registered direct offering totaling $5 million, according to a press release. Priced at-the-market under…

Aequus, Medicom join to commercialize products in US

December 18, 2019
Aequus Pharmaceuticals and Medicom Healthcare have entered into an exclusive agreement to commercialize ophthalmology products in the United States…

Perspective

Roche completes acquisition of Spark

December 17, 2019
Spark Therapeutics has accepted a tender offer for all outstanding shares of common stock at a price of $114.50 per share, allowing Roche to complete…

UK authority clears Roche acquisition of Spark

December 16, 2019
The U.K. Competition and Markets Authority has cleared Roche’s pending acquisition of Spark Therapeutics, ruling the deal would not negatively…